Merrion Pharmaceuticals Announces Positive Phase IIB Study for Orazol Tablet Form of Zoledronate IV Infusion at ASCO Annual Meeting
Weekly tablet delivers major new benefits for patients, doctors and payors: avoiding the need for burdensome and costly infusions and related infection risks; weekly tablet dosing offers potential for better safety and side effect profile of a ‘gold standard’ oncology drug. - June 06, 2009
Press Releases 1 - 1 of 1